Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

{
  "signal_id": "927fb93a-9977-f1f7-a687-e868cb8d22f0",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-07-23T12:00:00+00:00",
  "company": {
    "name": "Agilent",
    "domain": "agilent.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/agilent-receives-eu-approval-pd-120000343.html",
    "title": "Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Yahoo Finance",
    "excerpt": "Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA ® (pembrolizumab) SANTA CLARA, Calif., July 23, 2026 --( BUSINESS WIRE )--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with pembrolizumab, in accordance with the approved product labelling, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients. This approval marks the eighth CE-marked companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006 in the EU. \"Expanding access to precision oncology across regions is essential to improving patient outcomes,\" said Majken Nielsen, vice president and general manager of Agilent's Clinical Diagnostics Division. \"This EU approval builds on our commitment to...",
    "product": "PD-L1 IHC 22C3 pharmDx",
    "summary": "Agilent Technologies Inc. has received European Union (EU) certification for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic to identify patients with certain types of carcinoma who may be eligible for treatment with Merck's KEYTRUDA.",
    "location": "European Union",
    "planning": false,
    "image_url": "https://s.yimg.com/lo/mysterio/api/5D358AB246AF2E33007AA0BBA2AD29E31F3912D64CC293BAE4A8FE8E0913B11C/subgraphmysterio/resizefill_w1200_h485;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Fbusiness-wire.com%2F0251ce8e83e646557de63b04c26f8d2a",
    "confidence": 0.95,
    "product_data": {
      "name": "PD-L1 IHC 22C3 pharmDx",
      "full_text": "PD-L1 IHC 22C3 pharmDx, Code SK006",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-07-23T12:00:00Z",
    "location_data": [
      {
        "region": "Western Europe",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-07-23",
    "article_sentence": "Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy."
  }
}

curl https://signals.autobound.ai/v1/signals/927fb93a-9977-f1f7-a687-e868cb8d22f0 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"agilent.com","limit":20}'